Abstract: A biological information measurement device includes a sensor unit that detects predetermined biological information related to an organ of a living body, an A/D conversion unit that converts a measurement signal output from the sensor unit into a digital signal, a storage unit that stores information including a digital signal related to the measurement signal output from the A/D conversion unit, an analysis processing unit that determines presence or absence of a suspicion of an abnormality in the organ by analyzing the digital signal, and a measurement control unit that changes a sampling frequency related to A/D conversion of the measurement signal under a predetermined condition when the analysis processing unit has determined that a suspicion of an abnormality is present in the organ.

Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

Abstract: Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

Abstract: The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH?CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.

Abstract: A demultiplexing device includes a first demultiplexer configured to demultiplex a first input signal, a second demultiplexer configured to demultiplex a second input signal, and a switching circuit configured to set an input destination of signals demultiplexed and output by each of the first demultiplexer and the second demultiplexer based on data rates of the first and second input signals. A multiplexing device includes a first multiplexer configured to multiplex a first input signal, a second multiplexer configured to multiplex a second input signal, and a switching circuit configured to set an input destination of signals multiplexed and output by the first multiplexer and the second multiplexer based on data rates of the first and second input signals.

Abstract: The present invention provides a novel bicyclic or tricyclic heterocyclic compound represented by the formula (I) wherein ring A is an optionally substituted aromatic group, one of X1 and X2 is a carbon atom, and the other is a nitrogen atom, X3 is a nitrogen atom, or CR2, X4 is a nitrogen atom, or CR3, X5 is a sulfur atom, or —CH?CH—, Z1 is an oxygen atom, —C(R6)(R7)—, —NH—, —C(R6)(R7)—NH—, —NH—C(R6)(R7)—, —C(R6)(R7)—O—, —O—C(R6)(R7)—, or a single bond, one of Z2 and Z3 is CH and the other is a nitrogen atom, or both are nitrogen atoms, and other symbols are as defined in the DESCRIPTION, or a pharmacologically acceptable salt thereof.

Abstract: A demultiplexing device includes: a first demultiplexer configured to demultiplex a first input signal; a second demultiplexer configured to demultiplex a second input signal; and a switching unit configured to set an input destination of signals demultiplexed by each of the first demultiplexer and the second demultiplexer to one of the first demultiplexer and the second demultiplexer, based on a configuration of each of the first input signal and the second input signal.

Abstract: In a hollow fiber element constituting a separation membrane module for separating an organic vapor, at least one end part of a fiber bundle consisting of multiple hollow fiber membranes having a selective permeability is fixed and bound with a tube sheet formed by a cured material, in which an epoxy composition (A) has been cured by using a hardener (B). A glass transition temperature of said cured material is not less than 160° C., a minimum elongation at break thereof is not less than 7.0%, and an elution ratio thereof is less than 5%. For this reason, the hollow fiber element has enough endurance to retain a gas-tightness of an internal space of the hollow fiber membrane and an external space of the hollow fiber membrane even in use under organic vapor with an elevated temperature and high pressure.

Abstract: An asymmetric gas separation membrane made of an aromatic polyimide mainly containing repeating units having an ether bond which is heated at a temperature near a softening point (Ts) of the aromatic polyimide, and a method for separating methanol from a methanol-containing mixed organic vapor by allowing methanol to selectively permeate the asymmetric gas separation membrane using the membrane.

Abstract: A novel binuclear metal complex containing a biimidazole as a bridging ligand. The binuclear metal complex can be used as a material for an organic electroluminescence element.

Abstract: A novel binuclear metal complex containing a biimidazole as a bridging ligand. The binuclear metal complex can be used as a material for an organic electroluminescence element.

Abstract: An asymmetric gas separation membrane made of an aromatic polyimide mainly containing repeating units having an ether bond which is heated at a temperature near a softening point (Ts) of the aromatic polyimide, and a method for separating methanol from a methanol-containing mixed organic vapor by allowing methanol to selectively permeate the asymmetric gas separation membrane using the membrane.

Abstract: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein each R1 represents hydrogen atom or the like; X represents oxygen atom or the like; A represents a C3-C7 cycloalkyl group, a C6-C10 aryl group or a heterocyclic group; R6 represents a halogen atom or the like; s represents 0 or an integer of 1 to 5; Q represents a pyridine ring which may be substituted or pyrimidine ring; and R2 represents hydrogen atom or the like, which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: An asymmetric hollow fiber gas separation membrane obtained by subjecting an asymmetric hollow fiber polyimide membrane to a heat treatment having a maximum temperature of from 350 to 450° C., wherein the asymmetric hollow fiber polyimide membrane is formed with a polyimide essentially having a repeating unit represented by a general formula (1); is excellent in a solvent resistance and a thermal stability, and as well has such a mechanical strength that a tensile elongation at break is not less than 10% as a hollow fiber membrane.

Abstract: A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein R2 represents a hydrogen or the like; R3 represents methyl group or the like; R20 represents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; R4 represents hydrogen or the like; R5 represents hydrogen or the like; R6 represents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH2, oxygen atom, NH, or the like; any one or more of R5 and R6, R5 and R4, R6 and R4, X and R5, X and R4, X and R6, and R6 and R6 may combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

Abstract: The present invention provides an orally administered composition and a dietary composition, which have a serum lipid improving effect. The orally administered composition and dietary composition, having a serum lipid improving effect, according to the present invention camp rise 2.0% by weight or less of a DHA ethyl ester composition comprising 75% by weight or more of DHA ethyl ester. It is preferable to comprise 1.2% by weight or less of the DHA ethyl ester composition. It is preferable not to substantially comprise a DHA ethyl ester composition comprising 30% by weight or less of DHA ethyl ester.

Abstract: There is disclosed an asymmetric gas separation membrane exhibiting both improved gas separation performance and improved mechanical properties, which is made of a soluble aromatic polyimide comprised of a repeating unit represented by general formula (1): wherein B in general formula (1) B comprises 10 to 70 mol % of tetravalent unit B1 represented by general formula (B1) and 90 to 30 mol % of tetravalent unit B2 represented by general formula (B2), and A in general formula (1) comprises 10 to 50 mol % of bivalent unit A1 represented by general formula (A1a) or the like and 90 to 30 mol % of bivalent unit A2 represented by general formula (A2a) or the like.

Abstract: Disclosed are a gas separation membrane and a gas separation method in which at least one species of organic vapor is separated and recovered from an organic vapor mixture using the gas separation membrane. The gas separation membrane is made of an aromatic polyimide composed of a tetracarboxylic acid component consisting of an aromatic ring-containing tetracarboxylic acid and a diamine component comprising 10 to 90 mol % of a combination of (B1) 3,4?-diaminodiphenyl ether and (B2) 4,4?-diaminodiphenyl ether at a B1 to B2 molar ratio, B1/B2, ranging from 10/1 to 1/10, and 10 to 90 mol % of other aromatic diamine.

Abstract: A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).